NEW YORK – ERS Genomics said on Tuesday that it has granted German startup company Vivlion a non-exclusive license to its CRISPR-Cas9 patent portfolio, which Vivlion will use to improve its own gene editing reagents and screening services.
Financial and other terms of the deal were not disclosed.